Background: The outcome of patients with bacteremia depends on both, the bacterial burden as well as the duration of bacteremia. Promptly decreasing bacterial load in the blood by using extracorporeal devices in addition to anti-infective therapy has recently been explored. Preclinical studies with Seraph® 100 Microbind® Affinity Blood Filter (Seraph® 100), which consists of heparin that is covalently bound to polymer beads, have demonstrated an effective binding of bacteria and viruses. Pathogens adhere to the heparin coated polymer beads in Seraph® 100 as they would normally do to heparan sulfate on cell surfaces. Using this biomimetic principle, the Seraph® 100 could help to decrease bacterial burden in vivo.Methods: This first in human, prospective, multicenter, non-randomized interventional study included patients with blood culture positive bloodstream infection and the need for renal replacement therapy as an adjunctive treatment for bloodstream infection. We performed a single four-hour hemoperfusion treatment with the Seraph® 100 in conjunction with a dialysis procedure. Post procedure follow up was 14 days.Results: Fifteen hemodialysis patients (3F/12M, age 74.0 [68.0 - 78.5] years, dialysis vintage 28.0 [11.0 - 45.0] months) were enrolled. Seraph® 100 treatment started 66.4 [45.7 - 80.6] hours after the positive initial blood culture was drawn. During the treatment with the Seraph® 100 with a median blood flow of 285 [225 - 300] ml/min no device or treatment related adverse events were reported. Blood pressure and heart rate remained stable while peripheral oxygen saturation improved during the treatment from 98.0 [92.5 - 98.0] to 99.0 [98.0 - 99.5] %; p = 0.0184. Four patients still had positive blood culture at the start of Seraph® 100 treatment. In one patient blood cultures turned negative during treatment. The time to positivity (TTP) was reduced between inflow and outflow blood cultures by 36 [-7.2 – 96.3] minutes. However, overall TTP reduction was not significant.Conclusions: Seraph® 100 treatment was well tolerated. Adding Seraph® 100 to antibiotics early in the course of bacteremia might result in a faster resolution of bloodstream infections, which has to be evaluated in further studies.Trail registration: ClinicalTrials.gov Identifier: NCT02914132